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Infiltrative Cardiovascular Diseases
Cardiomyopathies That Look Alike
James B. Seward, MD,* Grace Casaclang-Verzosa, MD†
Rochester, Minnesota
Infiltrative cardiomyopathies are characterized by the deposition of abnormal substances that cause the ventric-
ular walls to become progressively rigid, thereby impeding ventricular filling. Some infiltrative cardiac diseases
increase ventricular wall thickness, while others cause chamber enlargement with secondary wall thinning. In-
creased wall thickness, small ventricular volume, and occasional dynamic left ventricular outflow obstruction
(e.g., amyloidosis) can outwardly appear similar to conditions with true myocyte hypertrophy (e.g., hypertrophic
cardiomyopathy, hypertensive heart disease). Likewise, infiltrative disease that presents with a dilated left ventri-
cle with global or regional wall motion abnormalities and aneurysm formation (e.g., sarcoidosis) may mimic
ischemic cardiomyopathy. Low-voltage QRS complex was the sine qua non of infiltrative cardiomyopathy (i.e.,
cardiac amyloid). However, low-voltage QRS complex is not a uniform finding with the infiltrative cardiomyopa-
thies. The clinical presentation, along with functional and morphologic features, often provides enough insight to
establish a working diagnosis. In most circumstances, however, tissue or serologic evaluation is needed to vali-
date or clarify the cardiac diagnosis and institute appropriate therapy. (J Am Coll Cardiol 2010;55:1769–79)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.040a
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Enfiltrative cardiomyopathies are characterized by the dep-
sition of abnormal substances that cause the ventricular
alls to become progressively rigid, thereby impeding ven-
ricular filling. Some infiltrative cardiac diseases increase
entricular wall thickness (Table 1), while others cause
hamber enlargement with secondary wall thinning (Table 2).
he clinical presentation, along with functional and morpho-
ogic features, often provides enough insight to establish a
orking diagnosis. However, in most circumstances, tissue or
erologic evaluation is needed to validate or clarify the cardiac
iagnosis and institute appropriate therapy. This report high-
ights the unique features of the various infiltrative cardiac
iseases, which may have similar features.
nfiltrative Heart Disease
eneral considerations. CARDIAC FUNCTION ASSESSMENT.
nfiltrative diseases of the heart are generally characterized
y progressive diastolic dysfunction, which typically pre-
edes the development of overt systolic dysfunction. Al-
hough increased myocardial mass is characteristic of most
nfiltrative diseases, the quantification of mass is usually not
major determinant of survival. Doppler echocardiography
as simplified the assessment of diastolic physiology and
rom the *Divisions of Cardiovascular Diseases, General Internal Medicine, and
ediatric Cardiology, and the †Mayo Clinic College of Medicine and Echocardiog-
aphy Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester,
innesota.p
Manuscript received February 2, 2009; revised manuscript received December 7,
009, accepted December 7, 2009.trial remodeling, which are hallmarks of the restrictive
isease process. The chronicity of diastolic dysfunction is
est characterized by depressed Doppler myocardial relax-
tion velocity (mitral annular E tissue velocity) and in-
reased left atrial volume index (1). Systolic dysfunction is
ommonly measured as a decrease in the ejection fraction or
ystolic tissue Doppler velocity (2).
The role of computed tomography and cardiac magnetic
esonance (CMR) imaging and late gadolinium enhance-
ent (LGE) in providing incremental information for risk
ssessment in infiltrative cardiomyopathies has not been
dequately established. However, cardiac structure, func-
ion, and tissue characteristics can be obtained by CMR
GE. Gadolinium causes magnetic hyperenhancement in
onditions in which extracellular space is expanded (i.e.,
yocyte necrosis, myocardial edema, scar formation, and
rotein infiltration) (3,4). CMR has been used to charac-
erize the type of infiltrative disease by the location and
istribution of LGE and enable the evaluation of disease
ctivity and response to therapy. The sensitivity of CMR in
atients with early disease who do not have abnormal
ndings on echocardiography is unknown. However,
creening of subclinical early cardiac involvement may
ecome possible should CMR LGE prove to have adequate
ensitivity in detecting amyloid infiltration. The abnormal-
ties in myocardial and blood pool kinetics hold the promise
f serial quantification of cardiac amyloid load and treat-
ent follow-up.
lectrophysiologic considerations. It is important to em-
hasize that wall thickness is not necessarily a reliable
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Infiltrative Cardiomyopathies April 27, 2010:1769–79indicator of hypertrophy. Infiltra-
tive disorders, with accumulation
of abnormal substances within
myocytes or the myocardial inter-
stitium, may cause increased wall
thickness without actual myocyte
hypertrophy. Consequently, in-
creased wall thickness does not
consistently correlate with an in-
crease in QRS complex amplitude.
In fact, QRS complex amplitude
can become decreased (low volt-
ge), a phenomenon more commonly observed with accumu-
ations within the interstitium than within myocytes. The
bsence of increased voltage on the electrocardiogram (ECG)
espite the appearance of “hypertrophy” can be the first clue to
ertain infiltrative diseases (e.g., cardiac amyloid, Friedreich
taxia). However, low-voltage QRS complex is not a uniform
nding with the infiltrative cardiomyopathies. Some infiltrative
yopathies have increased voltage (e.g., Danon and Fabry
iseases), which will be seen when there is an increase in the
ize of cardiac myocytes, normal intraventricular conduction,
nd synchronous activation occurring globally in the myocar-
ium (Table 1).
enetic testing. The role of genetic testing in differenti-
ting phenocopies of left ventricular (LV) hypertrophy is
vident when clinical or imaging data are inconclusive.
enetic testing is now available on a clinical basis for several
f the genes responsible for cardiomyopathies. However, it
as its limitations and challenges. Testing sensitivity is low,
nd there may be more than 1 genetic variant in an affected
atient or within a single family. Other challenges of genetic
valuation, especially in children, include age-dependent
enetrance, the management of asymptomatic children, the
sychological effects of testing asymptomatic minors, and
xpense (5,6).
eneral management. Most infiltrative diseases have until
ecently been considered irreversible, and supportive mea-
ures were the only available means of management. Gen-
ral management consists of improving diastolic function
ith angiotensin receptor blockers and angiotensin-
onverting enzyme inhibitors. Beta-blockers and statins,
hich are known to be useful for heart failure management,
ay be of benefit. Systolic hypertension and overt fluid
verload can justify the cautious use of thiazide diuretics.
xcessive or protracted diuresis (i.e., using loop diuretics)
hould be avoided in the presence of hypovolemia and small,
oncompliant ventricular cavities. Novel treatment modal-
ties will be briefly discussed when applicable.
nfiltrative Cardiomyopathies That Look Like
ypertrophic or Hypertensive Heart Disease
ardiac amyloid. Cardiac amyloid is the prototype of infil-
rative heart disease with increased wall thickness (Fig. 1).
Abbreviations
and Acronyms
CMR  cardiac magnetic
resonance
ECG  electrocardiogram
HCM  hypertrophic
cardiomyopathy
LGE  late gadolinium
enhancement
LV  left ventricularardiac involvement is common in all forms of amyloidosis wnd is the most frequent cause of morbidity and mortality (7).
ymptoms include heart failure (i.e., breathlessness and exer-
ise intolerance), arrhythmias, conduction block, dynamic ven-
ricular outflow obstruction, and hypotension.
Characteristic echocardiographic appearance of cardiac
myloid includes increased thickness of both LV and right
entricular walls, normal or small LV cavity size, and a
onspecific granular appearance of the myocardium (Fig. 2).
trial enlargement, thickened papillary muscles, and valve
eaflets and small to moderate pericardial effusion are also
ommonly present. LV compliance gradually decreases as
yocardial deposition of amyloid fibrils progresses (8).
rogressive diastolic dysfunction is a universal finding (8).
ystolic dysfunction is typically evident only in advanced
tages (9). Doppler echocardiography is used to establish
nd serially monitor the magnitude of diastolic and systolic
ysfunction. CMR will show diffuse LGE throughout both
entricles, particularly the subendocardium (3).
Despite increased ventricular wall thickness, 30% to 50%
f patients with demonstrable amyloid disease will have
ormal-voltage QRS complexes, and the remainder show
ow-voltage complexes. A pseudoinfarction pattern, partic-
larly in the inferoseptal wall, may be observed in the
recordial leads (10). A decrease in QRS complex amplitude
ccurs because of myocyte atrophy along with decreased
onduction velocity and dyssynchronous activation resulting
rom amyloid deposition (11,12).
Cardiac amyloidosis is diagnosed either directly by endo-
yocardial biopsy or indirectly using noninvasive diagnostic
ools (2-dimensional echocardiography, magnetic resonance
maging, and ECG) and histologic confirmation of amyloid
n a noncardiac tissue specimen. Upon unequivocal estab-
ishment of the diagnosis and tissue confirmation of amyloid
ype, prompt therapy is warranted for primary amyloidosis
o arrest or reverse cardiac dysfunction (Fig. 3). Poor cardiac
eserve severely narrows the management strategies in the
ate stages (7,13). Untreated patients have a median survival
f 6 months after the onset of heart failure (13). Melpha-
an, steroids, immunomodulating agents, and stem cell
ransplantation after chemotherapy yield promising results
14–17). However, the mortality rate of transplantation
anges from 11% to 40% (18,19). In some patients with
dvanced cardiac involvement, cardiac transplantation may
e performed before stem cell transplantation (20,21).
abry disease. Fabry disease is an X-linked autosomal
ecessive disease due to a lack of lysosomal enzyme,
-galactosidase A, which breaks down neutral glycosphin-
olipids (22). This causes intracellular lysosomal accumula-
ion of ceramide trihexoside (globotriaosylceramide), pri-
arily in the skin, kidneys, and heart (22). Men are
ommonly affected, with the condition diagnosed early in
hildhood, but cardiac involvement is not manifested until
he third or fourth decade of life (23). Cardiac involvement
n Fabry disease can mimic the morphologic and clinical
eatures of hypertrophic cardiomyopathy (HCM; very thick
alls, systolic anterior motion of the anterior mitral valve
Conditions Presenting With Increased LV Mass and Thick Ventricular WallsTable 1 Conditions Presenting With Increased LV Mass and Thick Ventricular Walls
Condition Age at Presentation History and Clinical Presentation Echocardiography ECG Profile CMR LGE Biopsy Ref. #
Cardiac amyloid 30 yrs Heart failure symptoms, nephrotic
syndrome, idiopathic peripheral
neuropathy, unexplained
hepatomegaly
Symmetrical increase in LV and
RV wall thickness, dilated LA
and RA, granular appearance
of myocardium, pericardial
effusion, decreased EF in
advanced cases
Decreased or normal QRS complex
voltage, pseudoinfarction in
inferolateral leads
Global, diffuse, pronounced
in subendocardium;
RV and LV walls
Myocyte atrophy, amyloid
replaces normal
cardiac tissue
(3,7,10)
Fabry disease Male: 11 7 yrs;
female: 23 16 yrs
Neuropathic pain, impaired
sweating, skin rashes
Symmetrical increase in LV and
RV wall thickness, normal EF
Increased or normal QRS complex
voltage, short or prolonged PR
interval
Focal, midwall, inferolateral
wall
Enlarged myocytes with
clusters of concentric
glycolipid (myelinoid
bodies) within
lysosomes
(3,22,28,29)
Danon disease 20 yrs Heart failure, skeletal myopathy,
mental retardation
Very thick LV (20–60 mm),
RV may or may not be thick,
decreased EF
Increased or normal QRS complex
voltage, short PR interval (delta
wave)
Subendocardial, does not
correspond to perfusion
territory
Sarcoplasmic
vacuolization, focal
storage of PAS-positive
material, myofibrillar
disarray
(32,34,36)
Friedreich ataxia 25 yrs
(range 2–51 yrs)
Gait abnormality Increase in LV septal and
posterior wall thickness,
normal EF
Normal QRS complex voltage,
ventricular tachycardia
Nonspecific (41,42,44,47)
Cardiac oxalosis 20 yrs Juvenile urolithiasis and
nephrocalcinosis
Symmetrical increase in LV and
RV wall thickness; patchy,
echodense speckled
reflection; normal EF
Increased or normal QRS complex
voltage, complete heart block
Increased myocardium
attenuation on CT
Intra- and extracellular
deposition of oxalate
crystals without
concomitant
inflammation and
necrosis
(49,50,51)
Mucopolysaccharidoses 1–24 yrs
(median, 10 yrs)
Variable depending on subtype,
coarse facial features, delayed
mental development, skeletal
deformities, corneal clouding,
hepatosplenomegaly
Asymmetrical septal
hypertrophy, mitral and/or
aortic valve stenosis or
insufficiency, normal EF
Increased or decreased QRS
complex voltage, malignant
arrhythmia
Swollen myocytes with
clear cytoplasm due to
accumulation of
mucopolysaccharides
within lysosomes
(12,53,55,56)
Differential diagnosis
Hypertrophic
cardiomyopathy
17–18 yrs Maybe asymptomatic, dyspnea,
angina, syncope, sudden death
Asymmetrical hypertrophy,
small LV cavity, LVOT
obstruction, normal EF
Increased QRS complex voltage,
pseudo–delta wave, giant
T-wave inversion
Patchy, midwall, junctions
of the ventricular septum
and RV
Myocyte hypertrophy,
myofibrillar disarray,
and interstitial fibrosis
(4)
Hypertensive heart
disease
Adults History of hypertension Symmetrical increase in LV wall
thickness, mild LV dilation,
normal EF
Increased QRS complex,
nonspecific ST-T-wave changes
No pattern, predominantly
subendocardial
Enlarged myocytes with
enlarged or replicated
nuclei
(4)
CMR  cardiac magnetic resonance; CT  computed tomography; ECG  electrocardiogram; EF  ejection fraction; LA  left atrium; LGE  late gadolinium enhancement; LV  left ventricle; LVOT  left ventricular outflow tract; RA  right atrium; RV  right ventricle.
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Conditions With Dilated LV and Infarct PatternTable 2 Conditions With Dilated LV and Infarct Pattern
Condition Age at Presentation History Echocardiography ECG CMR LGE Cardiac Biopsy Ref. #
Sarcoidosis Young adults Congestive heart failure Variable wall thickness, focal
or global hypokinesis,
LV aneurysm
Infrahisian block, atypical
infarction pattern
Patchy, basal and lateral
LV walls
Noncaseating, multinucleated
giant cell granuloma
surrounded by band of
dense collagen fibers
(62,63,65,70)
Wegener disease Young adults Chronic upper and lower
respiratory tract infections
Regional hypokinesis,
pericardial effusion, mild
MR, LV systolic
dysfunction
Atrial fibrillation,
atrioventricular block,
atypical infarction
pattern
Diffuse, midwall Vasculitis with necrotizing
granulomatous
inflammation
(74,75)
Hemochromatosis Hereditary hemochromatosis:
30 yrs in men, older in
women; secondary
hemochromatosis: any age
Hereditary hemochromatosis:
liver function abnormalities,
weakness and lethargy, skin
hyperpigmentation, diabetes
mellitus, arthralgia, impotence
in men; secondary
hemochromatosis: hemolytic
anemia, multiple blood
transfusions
Dilated LV with global
systolic dysfunction
Supraventricular
arrhythmia, ventricular
conduction
abnormality is rare
Iron deposits within the
myocyte
(4,77–79)
Differential
diagnoses
Ischemic
cardiomyopathy
Adult Coronary artery disease,
congestive heart failure
Dilated LV, regional
hypokinesis corresponding
to perfusion territory,
decreased systolic
function
Multiform premature
ventricular complexes,
nonsustained
ventricular tachycardia
Subendocardial, different
degrees of transmural
extension, corresponds
to perfusion territory
(3,78)
Idiopathic dilated
cardiomyopathy
Adult Congestive heart failure, no
known cardiovascular disease
Dilated LV with global
systolic dysfunction
Atrial fibrillation No LGE, or if present,
midwall and patchy
(3,78)
MR  mitral regurgitation; other abbreviations as in Table 1.
1772
Sew
ard
and
Casaclang-Verzosa
JACC
Vol.55,No.17,2010
Infiltrative
Cardiom
yopathies
April27,2010:1769–79
l
H
s
i
w
o
s
d
i
p
d
p
m
s
c
a
c
h
p
s
u
L
t
d
D
X
a
e
A
s
c
c
d
g
i
t
s
o
r
p
w
s
n
i
v
H
d
k
c
e
p
P
s
a
v
a
t
t
c
b
s
t
w
t
o
v
a
m
F
n
1773JACC Vol. 55, No. 17, 2010 Seward and Casaclang-Verzosa
April 27, 2010:1769–79 Infiltrative Cardiomyopathieseaflet) and accounts for 3% of cases initially diagnosed as
CM (24,25). However, asymmetrical hypertrophy causing
evere LV outflow tract obstruction and significant mitral
nsufficiency are typically absent in Fabry disease (26). LV
all thickness and LV mass increase as age and the severity
f disease advance (22). Ejection fraction and fractional
hortening are usually preserved (22). Progressive diastolic
ysfunction is evident, but restrictive filling pattern is an
nfrequent finding (22). On 2-dimensional echocardiogra-
hy, nonspecific binary appearance of the endocardial bor-
er corresponding to endomyocardial sphingolipid com-
artmentalization, creating a 2-layered appearance of the
yocardium, has been observed (24,27). CMR will typically
how focal inferolateral midwall LGE sparing the subendo-
ardium (3,28). Progressive diastolic dysfunction best char-
cterizes the prognosis.
Fabry disease is not associated with decreased QRS
omplex amplitude but rather shows ECG features of LV
ypertrophy commensurate with the wall thickness (29). A
attern of pre-excitation can be seen (29). However, in
ome cases, when deposition occurs within the atrioventric-
lar node, the PR interval may be prolonged (30).
Enzyme replacement therapy has been shown to reduce
V wall thickness and improve regional myocardial func-
ion, but its effect on survival has yet to be adequately
etermined (31).
anon disease. Like Fabry disease, Danon disease is a rare
-linked disorder due to primary deficiency of lysosome-
ssociated membrane protein 2 (32,33). It affects men at an
arly age (in the teens) and women in later years (in the 20s).
ffected men typically present with a triad of heart failure,
keletal myopathy, and mental retardation (34). In female
arriers, the disease predominantly affects the cardiac myo-
ytes (35).
Cardiac symptoms begin during adolescence, and patients
ie of heart failure in their third decade (34). Echocardio-
raphic characteristics include a marked symmetrical increase
Figure 1 Two Hearts From Autopsy (Short-Axis Views) Showing
(A) Amyloidosis; (B) hypertrophic cardiomyopathy. Clinically, both hearts were cha
Without additional information (such as electrocardiographic or endomyocardial bion LV wall thickness (range 20 to 60 mm), significantly greater Ahan that typically found in patients with HCM (32). LV
ystolic dysfunction is often severely impaired (32,34). LV
utlet obstruction is uncommon (34). A prominent increase in
ight ventricular wall thickness (10 mm) in the absence of
ulmonary disease may also be observed (32). Unlike HCM, in
hich LGE is midepicardial and patchy, Danon disease has
ubendocardial LGE (36).
Unlike amyloidosis, Danon disease is a myocyte disorder,
ot an interstitial one, and thus is associated with normal or
ncreased QRS complex amplitude. In addition, conduction
elocity (pre-excitation) may be enhanced (37,38). Unlike
CM, Danon disease and associated glycogen storage disor-
ers (lysosome-associated membrane protein 2 or protein
inase, adenosine monophosphate-activated, gamma 2 non-
atalytic subunit mutations) are associated with true pre-
xcitation and the presence of single or multiple accessory
athways (37,38). Short PR interval and delta waves (Wolff-
arkinson-White syndrome) is a common finding causing
yncope in most patients (34). Palpitations or documented
rrhythmias in patients with this disorder may be related to the
entricular myopathic process (ventricular tachycardia) or the
ccessory pathway (orthodromic or antidromic precipitating
achycardia).
Genetic testing for lysosome-associated membrane pro-
ein 2 gene mutation is definitive and is the major diagnostic
riterion in women (in whom the protein may be present
ecause of 1 normal X chromosome) (34). There is no
pecific treatment for Danon disease (34). Potentially life-
hreatening pre-excitation atrial fibrillation or atrial flutter
ith conduction through the accessory pathways should be
reated by ablation or sodium-channel blockers. The value
f cardiac transplantation has not been established, because
ery few patients live long enough (they die at very young
ges) to undergo transplantation (35,39). The most com-
on cause of death is severe heart failure (32,34).
riedreich ataxia. Friedreich ataxia is an autosomal recessive
eurodegenerative disorder caused by expanded Guanine-
kedly Thickened Left Ventricular Walls
zed by diastolic dysfunction.
dings), these 2 conditions can closely mimic each other.Mar
racteri
psy findenine-Adenine repeats (120 to 1,700 times, rather than the
u
a
G
t
d
9
i
d
w
(
c
A
a
p
V
d
s
m
8
p
t
d
f
s
t
t
c
o
p
t
M
1774 Seward and Casaclang-Verzosa JACC Vol. 55, No. 17, 2010
Infiltrative Cardiomyopathies April 27, 2010:1769–79sual 8 to 22) in the frataxin gene on chromosome 9 (40). The
ge at onset of symptoms ranges from 2 to 51 years (40).
enerally, the cardiac manifestations occur 4 to 5 years after
he onset of the neurologic disorders, but occasionally heart
isease occurs first (41). Cardiac disease eventually develops in
0% to 100% of patients (42).
Echocardiographic studies reveal differing patterns of
ncreased wall thickness unrelated to the duration of the
isease (43). Cardiac involvement is characterized by increased
all thickness of the interventricular septum or posterior wall
41,42,44) (Fig. 2). LV diastolic relaxation is reduced, but LV
avity size and ejection fraction are usually normal (42,44).
symmetrical septal hypertrophy and LV outflow obstruction
re rare (42,44). Severe heart failure can develop in some
atients with mild LV dilation and systolic dysfunction (41).
alvular insufficiency, if present, is usually mild (42). Noncar-
Figure 2 Conditions Presenting With Increased Left Ventricular
(A) Hypertrophic nonobstructive cardiomyopathy, (B) hypertensive heart disease w
(C) cardiac amyloid, (D) mucopolysaccharidosis, (E) cardiac oxalosis, and (F) Frieiac dyspnea and frequent respiratory infections are due to severe scoliosis and neuromuscular impairment of respiratory
uscles (41). The 10-, 20-, and 30-year survival rates are 96%,
0%, and 61%, respectively (45). Cause of death is intercurrent
ulmonary infection and cardiac dysfunction (12,41). At this
ime, the only known therapy is supportive. Investigational
rugs include idebenone (a free radical scavenger) and de-
eriprone (an iron chelator) (46).
Compared with HCM, QRS complex voltage may not
how the extent of LV hypertrophy (41,47). The reason for
he lack of QRS complex amplification is marked connec-
ive tissue replacement and slowing of intraventricular
onduction (41,47). Coronary artery disease, abnormalities
f the nerve and the ganglia, and changes in the myocytes
redispose these patients to regions of slow conduction and
he propensity for ventricular tachyarrhythmia (41,47).
yocardial oxalosis. Primary hyperoxaluria is a rare auto-
s and Thick Ventricular Walls
ondary renal failure,
ataxia. See text for descriptions.Mas
ith sec
dreichomal recessive disorder characterized by an enhanced
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April 27, 2010:1769–79 Infiltrative Cardiomyopathiesroduction of oxalic acid, leading to the deposition of
xalate crystals in different organs, particularly the heart and
he kidneys (48,49). Echocardiography demonstrates biven-
ricular symmetrically thickened walls (49,50) (Fig. 2).
jection fraction may be normal in the early stage of this
isease (50). In advanced cases, mild biventricular dilation
as been observed (50). In contrast to LV hypertrophy
ound in long-term dialysis patients, the myocardium in
yperoxaluria is characterized by patchy, echodense speck-
ed reflection most prominent in the papillary muscles
50,51). In the very late stages, computed tomography can
emonstrate oxalate deposits as increased attenuation of the
yocardium (Fig. 4). Diastolic function is severely im-
aired, with elevated filling pressures and restrictive filling
attern (49,50). Patients usually present with complete
trioventricular block and ventricular conduction abnormal-
ties correlating with diffuse extensive oxalate infiltration of
he cardiac conduction system (50,51). QRS complex volt-
ge is either increased or normal because of asymmetrical
nd heterogeneous involvement of the myocardium, which
an inconsistently exhibit true hypertrophy (51).
There has been no consistent effect of daily hemodialysis
r of combined liver-kidney transplantation to improve
xalate balance and reverse the echocardiographic abnor-
alities (51,52).
ucopolysaccharidoses. The mucopolysaccharidoses rep-
Figure 3 Dramatic Treatment Response
(A) Cardiac amyloid. Echocardiogram of a 37-year-old woman in New York Heart As
with mild pericardial effusion and grade 3 diastolic dysfunction. Five years after st
cardial effusion, and diastolic function is normal. The patient is now in New York H
55-year-old woman who presented with dyspnea and fatigue. The left ventricle is d
repeated therapeutic phlebotomy, LV cavity decreased in size, and systolic functioesent inborn errors of metabolism due to deficiencies inysosomal enzymes that break down glycosaminoglycans
53). The accumulation of partially degraded mucopolysac-
harides impairs proper cell function and leads to various
linical manifestations. These disorders are inherited in an
utosomal recessive manner and affect men and women
qually (54). Depending on the type of mucopolysacchari-
osis, affected patients may have normal intellect or may be
tion functional class IV. Left ventricular (LV) and right ventricular walls are thick
ll transplantation, the LV and right ventricular walls are normal, there is no peri-
ssociation functional class I. (B) Hemochromatosis. Echocardiogram of a
with marked systolic dysfunction (ejection fraction  16%). Six years after
oved (ejection fraction  69%).
Figure 4 Unenhanced Chest Computed Tomographic Scan
Increased attenuation of myocardium is seen (arrow),
compatible with advanced oxalate deposition.socia
em ce
eart A
ilated,
n impr
p
h
i
b
(
e
e
fi
e
m
p
s
L
v
g
m
a
u
i
d
s
t
m
a
t
I
I
C
a
t
w
d
t
d
(
m
c
i
r
a
(
c
(
d
m
a
o
o
w
D
a
f
o
n
l
e
d
s
(
L
d
p
o
l
U
fi
g
i
f
(
1776 Seward and Casaclang-Verzosa JACC Vol. 55, No. 17, 2010
Infiltrative Cardiomyopathies April 27, 2010:1769–79rofoundly retarded, experience developmental delay, or
ave severe behavioral problems (55). Cardiac disease occurs
n almost 100% of all subtypes of mucopolysaccharidoses,
ut the most severe cardiac involvement is seen in type I
Hurler-Scheie syndrome) (56). Prominent valvular thick-
ning, diffuse coronary artery narrowing, myocardial thick-
ning, and secondary pulmonary hypertension are common
ndings (12,56). Asymmetrical septal hypertrophy occurs
arly, followed by thickening of the valves (56,57). The
itral and the aortic valves are more frequently involved,
roducing insufficiency and/or stenosis (56) (Fig. 2). LV
ystolic function is usually normal (56). ECG evidence of
V hypertrophy is uncommon (53,56). Small QRS complex
oltages may be due to poor conductance of glycosamino-
lycans (56). Rare intraventricular conduction delay or
alignant arrhythmias have been reported (56).
Diagnosis often can be made through clinical examination
nd urine tests (excess mucopolysaccharides are excreted in the
rine). Enzyme assays (testing a variety of cells or body fluids
n culture for enzyme deficiency) are also used to provide
efinitive diagnosis of 1 of the mucopolysaccharidoses.
Valve replacement has been successful in patients with
evere mitral valve disease (58,59). Enzyme replacement
herapy and bone marrow transplantation showed improve-
ents in cardiac structure and function in both human and
nimal studies (60,61). Death occurs early and is often due
o cardiovascular complications (12,56).
nfiltrative Cardiomyopathies That Look Like
schemic or Nonischemic Dilated Cardiomyopathy
ardiac sarcoidosis. This granulomatous disease tends to
ffect the basal septum, atrioventricular node and atrioven-
ricular (His) bundle, focal regions in the ventricular free
alls, and the papillary muscles. Two-dimensional echocar-
iographic characteristics of cardiac sarcoid vary according
o disease activity and include wall thickening (13 mm)
ue to granulomatous expansion and wall thinning
7 mm) due to fibrosis. With scar retraction, aneurysms
Figure 5 Conditions With Dilated Left Ventricle and Infarct Pat
All 3 conditions can present with a dilated left ventricle with poor systolic function
filling pressure characterized by left atrial enlargement. Cardiac sarcoid has anay develop, especially if the patient has been treated with
orticosteroids (Fig. 5). Other echocardiographic features
nclude normal to dilated ventricular chambers, normal to
educed systolic function, global to segmental hypokinesia,
nd uniform thickening of left and right atrial endocardium
62,63). Segmental wall motion abnormalities characteristi-
ally do not conform to any particular coronary distribution
64). In contrast to idiopathic dilated cardiomyopathy,
yskinetic or akinetic segments are interspersed with nor-
okinetic segments, resulting in an uneven wall motion
bnormality in sarcoidosis (65). Pulmonary involvement
ccurs in 90% of patients with sarcoidosis, and the presence
f pulmonary artery hypertension is an ominous sign and
arrants referral for lung transplantation (66,67). Thus,
oppler echocardiographic examination should include the
ssessment of pulmonary pressures and right ventricular
unction to detect early signs of pulmonary hypertension.
Because of the varied echocardiographic presentations
f cardiac sarcoidosis, 2-dimensional echocardiography is
ot sensitive or specific enough to detect early or small
ocalized areas of myocardial involvement (68). Contrast-
nhanced magnetic resonance imaging and (18F-fluoro-2-
eoxyglucose positron emission tomography are more sen-
itive, and findings seem to correlate with disease severity
68,69). In contrast to ischemic cardiomyopathy, in which
GE always involves the subendocardium with different
egrees of transmural extension, LGE in cardiac sarcoid is
atchy and typically involves the basal and lateral LV walls
nly (70).
Atypical infarction pattern and infrahisian atrioventricu-
ar block are commonly observed on the ECG (65,68,71).
nlike idiopathic dilated cardiomyopathy, atrial flutter or
brillation is not common in cardiac sarcoid.
There are no randomized controlled trials to provide clear
uidance for the treatment of sarcoidosis with cardiac
nvolvement. Therefore, therapy should be supportive and
ollow general principles for the management of sarcoidosis
62,72).
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April 27, 2010:1769–79 Infiltrative Cardiomyopathiesegener granulomatosis. Wegener granulomatosis is char-
cterized by necrotizing granulomatous inflammation, with
asculitis affecting many organ systems, particularly the upper
nd lower respiratory tract and the kidneys (73). In a series of
5 patients with confirmed Wegener granulomatosis who
nderwent echocardiography, 26 (36%) had confirmed cardiac
bnormalities attributable to the disease (74). Regional wall
otion abnormalities were found in 17 (65%), mild mitral
egurgitation in 14 (54%), LV systolic dysfunction in 13 (50%),
nd pericardial effusion in 5 (19%) (74). Those with associated
ardiac abnormalities had a higher mortality rate (46%) than
hose without (39%) (74). Cardiac sarcoidosis is suspected
hen regional wall motion abnormalities occur in relatively
oung asymptomatic patients with low cardiovascular risk
rofiles and are not confined to a specific coronary artery
erritory (74). LGE in the midwall rather than the subendo-
ardium is consistent with fibrosis rather than infarction (75).
Management of Wegener granulomatosis requires a mul-
idisciplinary approach. Any patient with Wegener granu-
omatosis and cardiac involvement is classified as having
severe” disease, defined as being life threatening or placing
he affected organ at immediate risk for irreversible damage
76). Glucocorticosteroids and cyclophosphamide remain
he standard of care for remission induction.
emochromatosis. Hemochromatosis represents an iron
verload disorder or iron storage disease characterized by
he accumulation of excessive iron within the cells of various
nternal organs. It may result from a genetic defect (hered-
tary hemochromatosis) or from secondary causes (second-
ry hemochromatosis) (12).
Cardiac hemochromatosis (iron heart) is a weak heart
hat is characterized by systolic dysfunction. Only rarely is
iastolic dysfunction the dominant abnormality. Two-
imensional echocardiography may not be able to distin-
uish cardiac hemochromatosis from idiopathic dilated
ardiomyopathy (Fig. 4). CMR can detect and quantify
yocardial iron infiltration using T2 cardiovascular mag-
etic resonance imaging (77,78).
The QRS complex voltage and duration are generally
reserved because of the absence of marked fibrosis with
argely preserved cardiac myocytes and the nonconductive
roperty of iron (79). With advanced disease, the ECG can
ave abnormal results (low QRS complex voltage) with
epolarization abnormalities (79).
Liver biopsy is the definitive test for iron overload (80).
ith functional cardiac involvement, stainable sarcoplasmic
ron is demonstrable in right ventricular endomyocardial
iopsy tissues; normally, there is no stainable iron in the
eart. With time, excessive sarcoplasmic iron may cause
yocyte degeneration and delicate interstitial fibrosis (12).
Cessation of multiple blood transfusions, phlebotomy,
nd chelation therapy have been shown to reverse cardiac
bnormalities due to iron overload (81–83) (Fig. 3). Some
atients may require combined liver and heart transplanta-
ion (84).
1onclusions
he infiltrative cardiomyopathies are a diverse group of
ardiac diseases, which are characterized by the deposition
f abnormal substances within heart tissue that cause the
entricular walls to develop either diastolic dysfunction or,
ess commonly, systolic dysfunction. Although amyloid
eart disease is commonly cited as the prototype of infiltra-
ive heart disease, it does not exemplify the diversity of the
nfiltrative diseases. Because these disorders are relatively
are and their physiologic and morphologic characteristics
re so variable, they tend to be misdiagnosed. Doppler
chocardiographic evaluation and ECG, and CMR in some
ases, in conjunction with the clinical manifestations, play a
ital role in establishing an accurate diagnosis and planning
he appropriate treatment.
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